Site Logo
  • About
    • About us
    • Management Team
    • Board of Directors
    • Advisory Board
  • R&D
    • Immuno-oncology
    • Technology
    • Collaborations
    • Publications
    • Posters
  • Clinical program
  • Partnering
  • Investors
    • Overview
    • The share
    • Shareholder information
    • Nomination committee
    • Largest shareholders
    • Financial calendar
    • Reports & Presentations
      • Financial Reports
      • Presentations
      • Information Document
    • Events
    • Analyst coverage
    • IR Contact
    • National Prospectus 2024
  • News
    • Press releases & other news
    • Subscribe
  • Contact

post@lytixbiopharma.com

News

news

Press releases & other newsSubscribe
Oct 17, 2013
Lytix Biopharma featured several times in Nordic press

Denmark:

http://www.jv.dk/artikel/1626763:Udland--Haab-forude--Norske-forskere-har-udviklet---supermolekyle---mod-kraeft

http://ekstrabladet.dk/kup/sundhed/article2123128.ece

http://nyhederne.tv2.dk/samfund/2013-10-16-kur-mod-kræft-norsk-kræftmissil-vækker-opsigt

http://www.b.dk/globalt/norske-forskere-har-udviklet-supermolekyle-mod-kraeft

http://ing.dk/artikel/dansk-overlaege-begejstret-over-ny-norsk-kraeftvaccine-163510

http://www.dagens.dk/sundhed/ny-kur-mod-kr%C3%A6ft-p%C3%A5-vej

http://www.mx.dk/viden/videnskab/story/30608186

http://jyllands-posten.dk/nyviden/ECE6105225/nyt-kraeft-missil-fra-norge-vaekker-opsigt/

Ingeniøren

Iceland:

http://www.pressan.is/Frettir/Lesafrett/nytt-norskt-krabbameinslyf-vekur-mikla-athygli-og-vonir

Norway (in addition to seperate mentioned articles):

http://www.abcnyheter.no/nyheter/helse/2013/10/15/norsk-kreftmedisin-sprenger-kreftceller-og-skaper-immunitet

Back

Cookies

Disclaimer

Privacy

Terms and Conditions

© 2025 Lytix Biopharma AS